SanteChoraleV4, Main, Exploration, bibRecord, 000178

An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost.

Identifieur interne : 000178 ( Main/Exploration ); précédent : 000177; suivant : 000179

An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost.

Auteurs : Geoffrey Teehan [États-Unis] ; Robert L. Benz

Source :

Anemia [ 2090-1275 ] ; 2011.

RBID : pubmed:21541213

Abstract

Background. Erythropoietin deficiency and anemia occur in Chronic Kidney Disease (CKD) and may be treated with Erythropoietin Stimulating Agents (ESAs). The optimal hemoglobin, in non-End Stage Renal Disease CKD, is controversial. Methods. We review three recent randomized trials in anemia in CKD: CHOIR, CREATE, and TREAT. Results. CHOIR (N = 1432) was terminated early with more frequent death and cardiovascular outcomes in the higher Hb group (HR 1.34: 95% C.I. 1.03-1.74, P = .03). CREATE (N = 603) showed no difference in primary cardiovascular endpoints. Stroke was more common in the higher Hb group (HR 1.92; 95% C.I. 1.38-2.68; P < .001) in TREAT (N = 4038). Conclusions. There is no benefit to an Hb outside the 10-12 g/dL range in this population. To avoid transfusions and improve Quality of Life, ESAs should be used cautiously, especially in patients with Diabetes, CKD, risk factors for stroke, and ESA resistance.

DOI: 10.1155/2011/623673
PubMed: 21541213
PubMed Central: PMC3085324

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000175
to stream Main, to step Curation: 000172

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost.</title>
<author><name sortKey="Teehan, Geoffrey" sort="Teehan, Geoffrey" uniqKey="Teehan G" first="Geoffrey" last="Teehan">Geoffrey Teehan</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Nephrology, Lankenau Medical Center, Suite 130 MOBW, 100 Lancaster Avenue, Wynnewood, PA 19096, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Division of Nephrology, Lankenau Medical Center, Suite 130 MOBW, 100 Lancaster Avenue, Wynnewood, PA 19096</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Benz, Robert L" sort="Benz, Robert L" uniqKey="Benz R" first="Robert L" last="Benz">Robert L. Benz</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21541213</idno>
<idno type="pmid">21541213</idno>
<idno type="doi">10.1155/2011/623673</idno>
<idno type="pmc">PMC3085324</idno>
<idno type="wicri:Area/Main/Corpus">000175</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000175</idno>
<idno type="wicri:Area/Main/Curation">000172</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000172</idno>
<idno type="wicri:Area/Main/Exploration">000172</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost.</title>
<author><name sortKey="Teehan, Geoffrey" sort="Teehan, Geoffrey" uniqKey="Teehan G" first="Geoffrey" last="Teehan">Geoffrey Teehan</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Nephrology, Lankenau Medical Center, Suite 130 MOBW, 100 Lancaster Avenue, Wynnewood, PA 19096, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Division of Nephrology, Lankenau Medical Center, Suite 130 MOBW, 100 Lancaster Avenue, Wynnewood, PA 19096</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Benz, Robert L" sort="Benz, Robert L" uniqKey="Benz R" first="Robert L" last="Benz">Robert L. Benz</name>
</author>
</analytic>
<series><title level="j">Anemia</title>
<idno type="eISSN">2090-1275</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background. Erythropoietin deficiency and anemia occur in Chronic Kidney Disease (CKD) and may be treated with Erythropoietin Stimulating Agents (ESAs). The optimal hemoglobin, in non-End Stage Renal Disease CKD, is controversial. Methods. We review three recent randomized trials in anemia in CKD: CHOIR, CREATE, and TREAT. Results. CHOIR (N = 1432) was terminated early with more frequent death and cardiovascular outcomes in the higher Hb group (HR 1.34: 95% C.I. 1.03-1.74, P = .03). CREATE (N = 603) showed no difference in primary cardiovascular endpoints. Stroke was more common in the higher Hb group (HR 1.92; 95% C.I. 1.38-2.68; P < .001) in TREAT (N = 4038). Conclusions. There is no benefit to an Hb outside the 10-12 g/dL range in this population. To avoid transfusions and improve Quality of Life, ESAs should be used cautiously, especially in patients with Diabetes, CKD, risk factors for stroke, and ESA resistance.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">21541213</PMID>
<DateCompleted><Year>2011</Year>
<Month>07</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>09</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2090-1275</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>2011</Volume>
<PubDate><Year>2011</Year>
</PubDate>
</JournalIssue>
<Title>Anemia</Title>
</Journal>
<ArticleTitle>An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost.</ArticleTitle>
<Pagination><MedlinePgn>623673</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2011/623673</ELocationID>
<Abstract><AbstractText>Background. Erythropoietin deficiency and anemia occur in Chronic Kidney Disease (CKD) and may be treated with Erythropoietin Stimulating Agents (ESAs). The optimal hemoglobin, in non-End Stage Renal Disease CKD, is controversial. Methods. We review three recent randomized trials in anemia in CKD: CHOIR, CREATE, and TREAT. Results. CHOIR (N = 1432) was terminated early with more frequent death and cardiovascular outcomes in the higher Hb group (HR 1.34: 95% C.I. 1.03-1.74, P = .03). CREATE (N = 603) showed no difference in primary cardiovascular endpoints. Stroke was more common in the higher Hb group (HR 1.92; 95% C.I. 1.38-2.68; P < .001) in TREAT (N = 4038). Conclusions. There is no benefit to an Hb outside the 10-12 g/dL range in this population. To avoid transfusions and improve Quality of Life, ESAs should be used cautiously, especially in patients with Diabetes, CKD, risk factors for stroke, and ESA resistance.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Teehan</LastName>
<ForeName>Geoffrey</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Division of Nephrology, Lankenau Medical Center, Suite 130 MOBW, 100 Lancaster Avenue, Wynnewood, PA 19096, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Benz</LastName>
<ForeName>Robert L</ForeName>
<Initials>RL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2011</Year>
<Month>04</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Egypt</Country>
<MedlineTA>Anemia</MedlineTA>
<NlmUniqueID>101536021</NlmUniqueID>
<ISSNLinking>2090-1267</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year>
<Month>09</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2011</Year>
<Month>01</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>5</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>5</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2011</Year>
<Month>5</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">21541213</ArticleId>
<ArticleId IdType="doi">10.1155/2011/623673</ArticleId>
<ArticleId IdType="pmc">PMC3085324</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Am Soc Nephrol. 2009 Dec;20(12):2651-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19850955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Kidney Dis. 1995 Apr;25(4):548-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7702049</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2006 Nov 16;355(20):2085-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17108343</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Kidney Int. 2008 Nov;74(10):1237-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18596731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Intern Med. 2002 Jun 24;162(12):1401-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12076240</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Soc Nephrol. 1999 Jun;10 Suppl 13:S292-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10425612</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>World Health Organ Tech Rep Ser. 1968;405:5-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4975372</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Kidney Dis. 1991 Jul;18(1):50-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2063855</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Nov 19;361(21):2019-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19880844</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Oncol. 2005 Sep 1;23(25):5960-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16087945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Soc Nephrol. 2005 Jun;16(6):1803-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15857925</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2006 Nov 16;355(20):2071-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17108342</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Kidney Int Suppl. 2002 May;(80):35-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11982810</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 1987 Nov 28;2(8570):1227-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2890852</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2009 May 2;373(9674):1532-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19410717</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Kidney Dis. 1999 Dec;34(6):1089-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10585319</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Kidney Int. 2001 Nov;60(5):1875-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11703606</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Kidney Dis. 1994 Jul;24(1 Suppl 1):S2-9; discussion S31-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8023835</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Soc Nephrol. 2002 Jul;13(7):1928-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12089390</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nephrol Dial Transplant. 1999;14 Suppl 2:61-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10334669</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ther Apher Dial. 2004 Dec;8(6):443-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15663544</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nephrol Dial Transplant. 1995;10 Suppl 2:3-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7644103</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1998 Aug 27;339(9):584-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9718377</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2007 Feb 3;369(9559):381-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17276778</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Pennsylvanie</li>
</region>
</list>
<tree><noCountry><name sortKey="Benz, Robert L" sort="Benz, Robert L" uniqKey="Benz R" first="Robert L" last="Benz">Robert L. Benz</name>
</noCountry>
<country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Teehan, Geoffrey" sort="Teehan, Geoffrey" uniqKey="Teehan G" first="Geoffrey" last="Teehan">Geoffrey Teehan</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SanteChoraleV4/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000178 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000178 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SanteChoraleV4
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:21541213
   |texte=   An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:21541213" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a SanteChoraleV4

This area was generated with Dilib version V0.6.37.
Data generation: Sat Oct 10 10:36:24 2020. Site generation: Sat Oct 10 10:37:38 2020

	Serveur d'exploration sur le chant choral et la santé
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le chant choral et la santé

An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost.

An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki